Financials( ₹ in Cr) | Aarti Pharmalabs Ltd | Sun Pharmaceuticals Industries Ltd | Divis Laboratories Ltd | Cipla Ltd | Torrent Pharmaceuticals Ltd |
---|---|---|---|---|---|
Price | 669.00 | 1,851.15 | 5,434.30 | 1,639.20 | 3,484.80 |
% Change | -0.82 | 0.30 | -0.09 | 0.67 | 1.43 |
Mcap ₹ Cr | 6,062.88 | 444,152.90 | 144,263.82 | 132,368.35 | 117,941.31 |
Revenue TTM ₹ Cr | 1,852.61 | 48,496.85 | 7,845.00 | 25,774.09 | 10,727.84 |
Net Profit TTM ₹ Cr | 216.90 | 9,648.44 | 1,600.00 | 4,155.31 | 1,656.38 |
PE TTM | 27.09 | 42.01 | 86.24 | 29.57 | 69.51 |
1 Year Return | 51.72 | 62.82 | 45.45 | 31.41 | 86.63 |
ROCE | 16.60 | 17.20 | 16.41 | 22.27 | 23.21 |
ROE | 13.08 | 16.13 | 12.15 | 16.58 | 25.38 |
Equity Capital: 1,757.04 Cr FV: 5.00
Period | MF Net Purchase / (sold) | FII Net |
---|---|---|
LAST 1M | 22,010.16 | 41,745.03 |
LAST 3M | 81,348.09 | 35,985.79 |
LAST 6M | 194,101.40 | 42,628.07 |
LAST 12M | 329,791.39 | 98,890.68 |
Date | Action Type | Ratio |
---|---|---|
Jul 31, 2024 | Dividend | 20 |
Feb 16, 2024 | Dividend | 40 |
Aarti Pharmachem Limited was incorporated as a Public Limited Company in 2019. The Company is engaged in manufacturer of Active Pharmaceutical Ingredients (API), Pharmaceutical Intermediates, New Chemical Entities (NCE), and Xanthine Derivatives situated in India. In 2001, the Company commissioned first API manufacturing Unit in Dombivali (Unit 1) and started Xanthine Unit; further it commissioned first API manufacturing Unit 4 in Tarapur for Regulated Markets in 2005; commissioned Caffeine production at Unit 5 with a capacity of 100 Metric Tonnes (MT) per month in 2016. It expanded block for CSD, Vapi and API, Tarapur units in 2022. The Scheme of Arrangement for the demerger of Pharma Business Undertaking from Aarti Industries Limited into its wholly owned subsidiary Aarti Pharmalabs Limited was effective on October 17, 2022 and operational from July 1, 2021. Pursuant to the said Demerger Scheme, Aarti Industries Limited hived off its Pharmaceutical Division into a separate entity `Aarti Pharmalabs Limited and accordingly, all the assets and liabilities pertaining to the Pharma Business Undertaking got transferred and vested into the Company effective from the above said Date. Thereafter, the Company in 2023 commercialised Block V at Tarapur Unit 4. Again, it enhanced Xanthine capacity to 5,000 TPA in 2023. 9,06,26,008 Equity Shares of Rs 5/- each got listed effective January 30, 2023.
AGM Date (Month) | : | Sep |
Face Value Equity Shares | : | 5 |
Market Lot Equity Shares | : | 1 |
BSE Code | : | 543748 |
NSE Code | : | AARTIPHARM |
Book Closure Date (Month) | : | |
BSE Group | : | A |
ISIN | : | INE0LRU01027 |
You can buy Aarti Pharmalabs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aarti Pharmalabs Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 12, 2024 10:09 AM the closing price of Aarti Pharmalabs Ltd was Rs.669.00.
The latest PE ratio of Aarti Pharmalabs Ltd as of Sep 12, 2024 10:09 AM is 27.09
The latest PB ratio of Aarti Pharmalabs Ltd as of Sep 12, 2024 10:09 AM is 0.29
The 52-week high of Aarti Pharmalabs Ltd share price is Rs. 721.70 while the 52-week low is Rs. 371.10
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 12, 2024 10:09 AM, the market cap of Aarti Pharmalabs Ltd stood at Rs. 6,062.88 Cr.